Navigation Links
EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
Date:12/9/2008

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients. The study will be conducted at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. Dr. Sherif Farag, Associate Professor, Department of Medicine, will serve as principal investigator.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Primary objectives for the dose escalation study include determining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 when administered orally once a day in patients with multiple myeloma who are refractory to other drug therapy. The study will also assess the safety, tolerability, pharmacodynamic effects and activity of ENMD-2076 in this patient population.

Preclinical data supporting the clinical evaluation of ENMD-2076 alone and in combination in multiple myeloma were presented by Dr. Farag earlier this week at the American Society of Hematology Annual Meeting in San Francisco, CA. ENMD-2076 was shown to induce rapid apoptosis (cell death) in multiple myeloma cell lines in vitro. Significant dose-dependent antitumor activity with minimal toxicity was also induced in vivo when ENMD-2076 was administered as a single agent in multiple myeloma models. Combination studies with ENMD-2076 and lenalidomide (Revlimid(R)) in vitro indicated synergistic cytotoxic activity towards several human multiple myeloma cell lines. ENMD-2076 was shown, both in vitro and in vivo, to have minimal toxicity towards human and murine h
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in ... surgeries. From vital sign monitoring in ICU to 3D skull printing analysis for ... make real-time clinical decisions with simultaneous access to high precision medical images and ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... of their entire waste to energy process and continue to contribute to the ... Upgrade , Temarry’s Waste to Energy process has been operating at their Mexico ...
(Date:9/2/2015)... Telford, England (PRWEB) , ... September 02, 2015 ... ... for drug discovery and life science research, today unveiled Genedata Screener ® ... platform for all in-vitro screening brings to market a rich set of new ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... Based on the 1918 Spanish Influenza Strain Protected Mice ... H5N1 Bird FluROCKVILLE, Md., April 14 ... (Nasdaq: NVAX ) today reported preclinical study ... vaccine based on the 1918 Spanish influenza strain protected ...
... the leading systems biology tools company, announced today that ... has joined the MetaMiner Stem Cell Partnership ... develop a series of blueprint pathway maps for adult, ... totipotent stem cells."We feel that it is important to ...
... Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., ... mL in PVC flexible containers to its existing Fluconazole ... is equivalent to Diflucan(R) by Pfizer. Fluconazole injection ... candidiasis, cryptococcal meningitis, and is also indicated for the ...
Cached Biology Technology:NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 3NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 5Children's Memorial Research Center, Chicago Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program 2Bedford Laboratories(TM) to Begin Shipping Fluconazole Injection in PVC Flexible Containers 2
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... Groundbreaking research has shown a quantum atom has been tracked ... in the testing and development of new drugs. Professor ... who led the research said it is the first time ... a sensor to explore the nanoscale environment inside a living ...
... Three teams of Tufts graduate students have won ... program for their research into solutions to some of ... water, development of renewable energy, and the creation of ... select number of universities that participate annually in the ...
... an economically and environmentally beneficial, ,bio-derived, Australian and ... proposition, according to a report compiled by CSIRO ... players.The report, Flight Path to Sustainable Aviation, predicts ... sustainable, Australia-New Zealand aviation fuels industry could cut ...
Cached Biology News:Quantum sensor tracked in human cells could aid drug discovery 2Tufts graduate students receive $10,000 prizes 2Sustainable 'bio-derived' jet fuel industry is achievable 2
... Precision-designed for Optimal Microdissection , CapSure HS ... precise and rapid extraction of populations of ... samples with Laser Capture Microdissection., Ensure ... Molecular Analysis , All CapSure LCM Caps ...
... Microdissection , CapSure HS and CapSure Macro ... extraction of populations of pure cells from ... Capture Microdissection., Ensure the Integrity of ... All CapSure LCM Caps have a patented ...
... detector is an optical unit that can ... or Dyad Disciple gradient-capable thermal cycler (purchased ... photonics shuttle that contains four LEDs for ... nm, 620-650 nm) and two filtered photodiodes ...
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
Biology Products: